STAAR Surgical Company — Form 10-K Summary
Reporting period: Fiscal year ended January 1, 2016, with quarterly data for fiscal fourth quarter 2015. The request metadata references “2014 Q4,” but the supplied filing is the fiscal 2015 Form 10-K.
Business Context
STAAR designs, manufactures and sells implantable ophthalmic lenses and delivery systems. Its principal products are Visian implantable Collamer lenses (ICLs) for refractive surgery and intraocular lenses (IOLs) for cataract surgery. The company sells in more than 60 countries and operates as one ophthalmic surgical products segment.
- International sales represented approximately 86% of fiscal 2015 revenue.
- ICLs represented 66.8% of sales; IOLs represented 25.8%; other surgical products represented 7.4%.
- China and Korea distributors each accounted for more than 10% of consolidated sales.
Financial Performance and Liquidity
| Metric | Fiscal 2015 | Fiscal 2014 | Change |
|---|---|---|---|
| Net sales | $77.1 million | $75.0 million | +2.8% |
| Gross profit | $52.7 million | $48.8 million | +8.0% |
| Gross margin | 68.4% | 65.1% | +330 bps |
| Operating loss | $5.3 million | $8.0 million | Improved |
| Net loss | $6.5 million | $8.4 million | Improved |
| diluted loss per share | $0.17 | $0.22 | Improved |
| Cash flow from operations | $(2.2) million | $(8.0) million | Improved |
Fiscal fourth-quarter 2015 revenue was $20.9 million, gross profit was $14.7 million, and net loss was $0.8 million, or $0.02 per diluted share. The filing does not provide a clearly stated fourth-quarter gross margin percentage, but gross profit divided by revenue was approximately 70.3%.
- ICL revenue increased 17.0% to $51.5 million, led by China, Korea, Germany and broader APAC and EMEA growth.
- IOL revenue declined 18.4% to $19.9 million, reflecting Germany’s distributor-to-direct transition, a planned China phase-out, softness in the U.S., and currency effects.
- Research and development expense rose 19.4% to $14.8 million, primarily due to remediation, validation and increased headcount.
- Marketing and selling expense declined 8.4% to $23.7 million; general and administrative expense increased 7.2% to $19.6 million.
- Cash and cash equivalents were $13.4 million at year-end; working capital was $31.2 million.
- Accounts receivable increased to $15.7 million from $11.1 million, and days sales outstanding increased to 74 days from 54 days. Inventory was $15.9 million, with days inventory on hand increasing to 178 days from 155 days.
- Debt consisted primarily of a $4.2 million Japanese line of credit, with no availability remaining under that facility. The company reported compliance with credit covenants.
- Total liabilities were $24.1 million and stockholders’ equity was $38.8 million. Defined-benefit pension plans were underfunded by approximately $3.9 million.
Material Changes Versus the Prior Period
- Revenue growth shifted substantially toward higher-margin ICL products, improving gross margin from 65.1% to 68.4%.
- ICLs increased from 58.7% to 66.8% of sales, while IOLs declined from 32.5% to 25.8%.
- Foreign currency movements reduced fiscal 2015 revenue by approximately $2.4 million and contributed to lower reported results in international markets.
- Operating and net losses narrowed despite continued investment in quality systems, regulatory activities and product development.
- Operating cash use improved by approximately $5.8 million, although the company remained cash-flow negative.
- On February 11, 2016, a shareholder’s ownership increase to approximately 26% triggered immediate vesting of all unvested equity awards. The company expects to record a $6.9 million non-cash stock-based compensation charge in the first quarter of fiscal 2016.
Guidance, Outlook and Management Commentary
- Management expects double-digit ICL unit growth over the following 12 months, driven primarily by CentraFLOW adoption in China and Europe.
- Management expects fiscal 2016 gross margin to exceed fourth-quarter 2015 gross margin and IOL sales to be similar to fiscal 2015.
- Operating expenses as a percentage of sales are expected to be slightly above the 2015 rate, with investments expected to outpace near-term revenue and gross-margin expansion.
- Expected fiscal 2016 spending includes approximately $2.1 million for FDA remediation, $4 million of capital expenditures for infrastructure and systems, and $2 million for branding and marketing.
- Management expects ex-U.S. profits to be in the mid-single-digit range as a percentage of ex-U.S. sales and believes existing cash and operating resources will fund foreseeable requirements.
- The company received CE Mark approval in December 2015 for the V5 ICL with CentraFLOW technology and an expanded optical zone.
Risks, Contingencies and Unusual Items
- The FDA’s 2014 Warning Letter and 2015 FDA-483 identified quality-system and manufacturing deficiencies. Until remediation is satisfactory, FDA approval of certain related Class III products, including the Toric ICL, may be delayed or withheld. The timing and outcome of U.S. TICL approval remain uncertain.
- STAAR faces intense competition from larger ophthalmic companies and laser refractive procedures, and has experienced historical IOL market-share losses.
- The company relies heavily on international sales, independent distributors and foreign currencies, particularly the yen, euro and Swiss franc; it does not actively hedge currency exposure.
- Manufacturing is concentrated, with Monrovia, California serving as the sole manufacturing site for ICLs and IOLs. Single-source materials and supply interruptions could materially affect production.
- The company has a history of losses, remains dependent on product revenue and operating cash flow, and may require additional financing if cash generation deteriorates.
- Pending matters include a putative securities class action concerning alleged regulatory disclosures and a dispute with Nidek regarding allegedly defective injectors. No loss was accrued because the likelihood and amount of loss were not estimable.
- U.S. federal net operating loss carryforwards were approximately $131.1 million, but management does not expect to utilize all of them before expiration; ownership changes may further restrict utilization.
- BDO USA, LLP issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management concluded that disclosure controls and internal controls were effective.
Investor Verification Checklist
- Confirm the filing period and reconcile fiscal 2015 results with the requested 2014 fourth-quarter reference.
- Track FDA remediation progress, warning-letter status and the timing of any U.S. TICL approval.
- Assess whether projected ICL growth offsets continued IOL weakness and elevated operating investment.
- Monitor cash flow, receivables, inventory days and the renewal of the Japanese credit facility due September 30, 2016.
- Evaluate the effect of the $6.9 million equity-award acceleration charge on first-quarter 2016 reported earnings.
- Review distributor concentration, currency sensitivity, manufacturing concentration and the outstanding securities and product-liability matters.